These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33245582)

  • 21. Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
    De Rosa L; Anghel G; Pandolfi A; Riccardi M; Amodeo R; Majolino I
    Int J Hematol; 2004 Jan; 79(1):85-91. PubMed ID: 14979484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
    Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of CD34
    Partanen A; Turunen A; Valtola J; Pyörälä M; Kuittinen O; Kuitunen H; Vasala K; Penttilä K; Kuittinen T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
    Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e428-e435. PubMed ID: 37684185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BeEAM vs. BEAM: evaluating conditioning regimens for autologous stem cell transplantation in patients with relapsed or refractory DLBCL.
    Wang R; Shangguan X; Zhu Z; Cong D; Bai Y; Zhang W
    Ann Hematol; 2024 Jul; 103(7):2455-2462. PubMed ID: 38809456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
    Grisariu S; Shapira MY; Or R; Avni B
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients.
    Wang T; Liu P; Xu L; Gao L; Ni X; Tang G; Chen L; Chen J; Wang L; Wang Y; Fu W; Yue W; Liu N; Li R; Lu G; Luo Y; Yang J
    Ann Hematol; 2024 Feb; 103(2):575-582. PubMed ID: 37932468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
    Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
    Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma.
    Lisenko K; Cremer M; Schwarzbich MA; Kriegsmann M; Ho AD; Witzens-Harig M; Wuchter P
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1397-1402. PubMed ID: 27060439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
    Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
    Knudsen LM; Gaarsdal E; Jensen L; Nielsen KJ; Nikolaisen K; Johnsen HE
    J Hematother; 1996 Aug; 5(4):399-406. PubMed ID: 8877715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
    Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
    Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
    Mercadal S; Briones J; Xicoy B; Pedro C; Escoda L; Estany C; Camós M; Colomo L; Espinosa I; Martínez S; Ribera JM; Martino R; Gutiérrez-García G; Montserrat E; López-Guillermo A;
    Ann Oncol; 2008 May; 19(5):958-63. PubMed ID: 18303032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
    Vose JM; Carter S; Burns LJ; Ayala E; Press OW; Moskowitz CH; Stadtmauer EA; Mineshi S; Ambinder R; Fenske T; Horowitz M; Fisher R; Tomblyn M
    J Clin Oncol; 2013 May; 31(13):1662-8. PubMed ID: 23478060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
    Shin HJ; Lee WS; Lee HS; Kim H; Lee GW; Song MK; Kim JS; Yhim HY; Chung JS
    Leuk Lymphoma; 2014 Nov; 55(11):2490-6. PubMed ID: 24432893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Montoro J; Andreola G; Gardellini A; Babic A; Negri M; Frungillo N; Martinelli G; Laszlo D
    Transfus Apher Sci; 2014 Jun; 50(3):411-4. PubMed ID: 24751603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.